Disruption of p53 in human cancer cells alters the responses to therapeutic agents - Test2 - elhamkhani - TriplyDB

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

http://www.wikidata.org/entity/Q33853609

about

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen High resolution melting for mutation scanning of TP53 exons 5-8 p53 regulation of G(2) checkpoint is retinoblastoma protein dependent Critical role for Daxx in regulating Mdm2 NIR, an inhibitor of histone acetyltransferases, regulates transcription factor TAp63 and is controlled by the cell cycle Negative regulation of p53 functions by Daxx and the involvement of MDM2 Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta MDMX regulation of p53 response to ribosomal stress Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression mRTVP-1, a novel p53 target gene with proapoptotic activities.Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy Activation of p53 in cervical carcinoma cells by small molecules.Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2 Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis Regulation of autophagy by cytoplasmic p53 A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways Induction of cullin 7 by DNA damage attenuates p53 function Prognostic Values of microRNAs in Colorectal Cancer Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells.Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin Apoptotic pathways as a therapeutic target for colorectal cancer treatment Mechanisms of drug resistance in colon cancer and its therapeutic strategies Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.Predictive value of CHFR and MLH1 methylation in human gastric cancer.Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.5-fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs.The role of p53 in cancer drug resistance and targeted chemotherapy Cell cycle regulation and p53 activation by protein phosphatase 2C alpha Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis Aspirin-induced nuclear translocation of NFkappaB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM BID regulation by p53 contributes to chemosensitivity Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells

P2860

Q21092375-1AABA050-F060-4D87-9E09-CE45891AE0EE Q21260416-18A98EE2-389A-4AC3-8ECA-F6E3CDE6EE07 Q22254140-7BBD0F74-C248-42FC-A8B3-4019DCD1B61F Q24297332-0F147D14-B41F-41FA-9C19-2921EB491354 Q24298090-DF60075D-F003-4E59-8746-5F5A99264F99 Q24303893-CE8A7CE3-B5CC-4F92-B3B0-6175ED4CFB90 Q24306430-E5FDB1A3-38FA-45BB-8EE4-6717C55BC4B2 Q24316958-76752413-697C-4E6C-B6F4-105596F24106 Q24529877-28B000A5-8075-4CA6-B9CC-8EDE29963B0D Q24537301-7791B3C1-F493-4A8E-8E74-61EF82D63106 Q24607826-D069B979-35A0-4443-BB64-7A295747856B Q24631354-6DA5DA68-8CB8-4D40-BC1D-E0F0DA8806BD Q24644964-E41B4CA8-47CE-44B5-A110-A656F5E6CF84 Q24648193-22DB5058-110C-48B3-943C-981C4216F00B Q24648286-B467187B-C673-44BD-BCC4-AE8C8A6D42D6 Q24651258-414B7FE0-3F85-4DA7-9685-575AED20E1D8 Q24669694-6BBEE3CA-5E65-4C91-9104-E64099F62124 Q24672443-C9FFFFD1-0CA5-42F4-9E68-9B2A381EC02D Q24675123-37BB156F-C0D9-413A-9CB6-717933C09AD0 Q24675258-FC4A11F1-6064-4040-8496-D6E754C62E93 Q24681379-55ED52BF-CBF2-408C-87B6-E1EBAB4CC138 Q24793084-E2EC1884-F812-4D0F-AD8B-C42AF60A2263 Q24801155-86AE3617-BF91-48FC-AC56-85CA102BF15D Q26738304-13FDF0A5-3645-445B-8859-ACCAD1458759 Q26738528-0F9B9FCA-825F-4AD6-AEA5-CF3812BCF166 Q26771601-71133603-49BF-4372-B39E-FECD38468804 Q27679062-C73B3D18-217B-4F05-8016-2BFF6B8E01E5 Q27851827-B94F3270-F85D-4F81-AB8E-54A06A4C45B5 Q27852067-D37BA423-E35E-47D9-BCA6-E25E14DE716F Q27852108-619FDCCB-6040-40E1-9AA8-BDEEDC6B6218 Q27852998-AB8BCA18-CCAD-4366-A7F6-A8310193EFBE Q27863385-F8BE9F4F-8782-4349-8441-FCA26851DAF2 Q27936402-110010EF-2E71-4E70-B471-BB21C4EC781C Q28072553-EC2DFFCB-A091-469E-B084-D724F04C908E Q28201863-27B3B5B9-EF9C-4FA1-B40B-77FF8263D4EB Q28204629-59701126-B404-400D-BB71-EC6E966CAD27 Q28210586-33CEBCEE-F34F-4D6C-8F56-41AFCB81578B Q28211000-AF020EFB-535B-482B-9CDE-3E5C92CEE62A Q28211208-7EAF4616-504B-4216-B5FA-60271DD47F17 Q28249223-E7DB494B-731F-445C-83E6-CF057E54EF6D

P2860

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

http://www.wikidata.org/entity/Q33853609

description

1999 nî lūn-bûn

@nan

1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

name

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

@ast

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

@en

type

label

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

@ast

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

@en

prefLabel

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

@ast

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

@en

P1433

Q33853609-159F514D-E64A-4696-A8C8-8DA1A9765683

P1476

Q33853609-E1FA4C9A-12F3-4CA3-81B5-F1351E0DB737

P2093

Q33853609-0163AC2B-FDD1-4D46-AC6B-ADB9C2BE1772

Q33853609-39617248-E6C6-495D-8D12-0011C5D26116

Q33853609-760BDB07-97D4-4C26-9DF8-7914FBD78A1A

Q33853609-974517E8-6603-46E1-B97E-206AB9CCA522

Q33853609-CE1EA284-FF0E-41AA-B706-849C4AF1FFA7

Q33853609-D04F7177-6042-432A-907D-5A1116BCE3BB

Q33853609-E8ED9D4F-E241-46CB-AFEE-472C26F55DF2

Q33853609-EE2FDEAF-B74B-45BC-969E-7B7815E38C41

P2860

Q33853609-0CA3718A-030B-4C0D-97D0-DCFE8498E096

Q33853609-11C82993-04B9-452C-96CF-182C8C13DFC6

Q33853609-2A10260F-647C-492B-A6D7-FD7B3F6C76D6

Q33853609-2A4D151D-EE9A-476C-A064-2F633241ABBF

Q33853609-340D2EFC-33CC-4032-819A-ACEE1E7A8830

Q33853609-38EB3203-60F6-489E-87CD-A37B331DE7EC

Q33853609-6E1D7E28-1DFB-4DD6-90FF-2FA11BC0D410

Q33853609-78E64C3C-0FE9-4233-97E1-B391EF67CA92

Q33853609-7E9FDC53-E996-4EF5-9376-6B5268B453C9

Q33853609-91748D05-8568-46CE-97FD-C1110B0E3123

P304

Q33853609-7F9444BE-DFBE-4C7F-87A6-A8A03FA91D58

P31

Q33853609-97AC12F4-49FB-4A81-96BD-482B523A0AAF

P356

Q33853609-5BC8121E-219E-47D0-8D6D-785781799690

P407

Q33853609-8CF44D63-4B29-40FF-A38A-60C7BBA1DAF2

P433

Q33853609-1138263D-4615-4CBC-B037-F2642B064290

P478

Q33853609-71348B69-F206-4B70-B982-2DB4450AD2AA

P50

Q33853609-1B533F17-03A7-4D73-8032-2DFDCEE0D466

Q33853609-AE8FC0CD-5215-4E89-A7E9-FA9E8BF33CD1

P577

Q33853609-230A7942-5C32-484E-B85D-1AD2E09AE3D2

P698

Q33853609-51F1251E-2646-4C15-9DB0-253C42609DB4

P932

Q33853609-F3D26B0E-175E-4027-996E-111BBDBF58CB

P356

P1433

Journal of Clinical Investigation

P1476

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

@en

P2093

C Lengauer

http://www.w3.org/2001/XMLSchema#string

C Torrance

http://www.w3.org/2001/XMLSchema#string

F Bunz

http://www.w3.org/2001/XMLSchema#string

J Williams

http://www.w3.org/2001/XMLSchema#string

L Dillehay

http://www.w3.org/2001/XMLSchema#string

P M Hwang

http://www.w3.org/2001/XMLSchema#string

T Waldman

http://www.w3.org/2001/XMLSchema#string

Y Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

A model for p53-induced apoptosis

p53, the cellular gatekeeper for growth and division

14-3-3sigma is a p53-regulated inhibitor of G2/M progression

p21 is necessary for the p53-mediated G1 arrest in human cancer cells

Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

Mitochondria and apoptosis

Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control

p53: puzzle and paradigm

Radiation-induced cell cycle arrest compromised by p21 deficiency

P304

263-269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI6863

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth W Kinzler

Bert Vogelstein

P577

1999-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10430607

http://www.w3.org/2001/XMLSchema#string

P932

408422

http://www.w3.org/2001/XMLSchema#string